LONDON, UK / ACCESSWIRE / December 13, 2017 / AFT Pharmaceuticals (NZSE: AFT) is a New Zealand-based specialty pharmaceutical company that currently sells over 130 prescription specialty generics and OTC products through its own salesforce in New Zealand, Australia and South-East Asia. It has been expanding its geographic footprint thanks mainly to Maxigesic, its paracetamol (acetaminophen)/ibuprofen combination product. Maxigesic is currently being sold in 10 countries and has distribution agreements in 124 in total. Further Maxigesic launches in the next two to three years should help drive revenues and margins.
We are reducing our valuation from NZ$461m or NZ$4.75 per share to NZ$460m or NZ$4.73 per share. We have reduced our near- and medium-term Maxigesic forecasts due to delayed launch timelines and reduced our estimates for Asian sales. The effect of these reductions was partly mitigated by higher estimates for Australia, higher gross margin estimates for the territories where AFT sells directly, as advancing our NPVs to the most recent period. Adjustments to launch timelines lead to delayed expected EBITDA break-even from FY18 to FY19.
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website
www.edisoninvestmentresearch.com
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Maxim Jacobs, +1 646 653 7027
Nathaniel Calloway, +1 646 653 7036
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-investment-research
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
SOURCE: Edison
